Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $297
Benzinga Newsdesk 14 hours ago
Analyst RatingsNewsPrice Target
Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target from $271 to $297.
Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target from $271 to $297.